ProCE Banner Activity

Selecting Therapy for AML with Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations

Slideset Download
Download these slides from a live webinar for the most recent data on selecting AML therapy for patients with predictive biomarkers or molecular alterations.

Released: July 28, 2022

Begin Activity

Share

Faculty

Amir Fathi

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc

Genentech, a member of the Roche Group

Jazz Pharmaceuticals Inc

Faculty Disclosure

Primary Author

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Amir T. Fathi, MD: consultant/advisor/speaker: AbbVie, Agios, Amgen, Astellas, Bristol-Myers Squibb, Celgene, Enclear, Foghorn, Forma, Genentech, Immunogen, Ipsen, Kite, Mablytics, MorphoSys, Novartis, Orum, PureTech, Servier, Takeda